

Scott R Evans

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8706187/publications.pdf>

Version: 2024-02-01

79
papers

3,566
citations

236925

25
h-index

138484

58
g-index

80
all docs

80
docs citations

80
times ranked

4597
citing authors

#	ARTICLE	IF	CITATIONS
1	Pragmatic trials of pain therapies: a systematic review of methods. <i>Pain</i> , 2022, 163, 21-46.	4.2	20
2	Short- vs Standard-Course Outpatient Antibiotic Therapy for Community-Acquired Pneumonia in Children. <i>JAMA Pediatrics</i> , 2022, 176, 253.	6.2	66
3	Independent Oversight of Clinical Trials through Data and Safety Monitoring Boards. , 2022, 1, .		10
4	Gastrointestinal Microbiome Disruption and Antibiotic-Associated Diarrhea in Children Receiving Antibiotic Therapy for Community-Acquired Pneumonia. <i>Journal of Infectious Diseases</i> , 2022, 226, 1109-1119.	4.0	6
5	A Desirability of Outcome Ranking Analysis of a Randomized Clinical Trial Comparing Seven Versus Fourteen Days of Antibiotics for Uncomplicated Gram-Negative Bloodstream Infection. <i>Open Forum Infectious Diseases</i> , 2022, 9, .	0.9	9
6	Time Course for Benefit and Risk of Ticagrelor and Aspirin in Acute Ischemic Stroke or Transient Ischemic Attack. <i>Neurology</i> , 2022, 99, .	1.1	7
7	Dalbavancin as an option for treatment of <i>S. aureus</i> bacteremia (DOTS): study protocol for a phase 2b, multicenter, randomized, open-label clinical trial. <i>Trials</i> , 2022, 23, 407.	1.6	19
8	On selecting the critical boundary functions in group-sequential trials with two time-to-event outcomes. <i>Contemporary Clinical Trials</i> , 2021, 101, 106244.	1.8	0
9	Sequential Multiple Assignment Randomized Trials for COMparing Personalized Antibiotic StrategieS (SMART COMPASS): Design Considerations. <i>Statistics in Biopharmaceutical Research</i> , 2021, 13, 181-191.	0.8	1
10	Real-World Data for Planning Eligibility Criteria and Enhancing Recruitment: Recommendations from the Clinical Trials Transformation Initiative. <i>Therapeutic Innovation and Regulatory Science</i> , 2021, 55, 545-552.	1.6	8
11	Antibacterial Resistance Leadership Group 2.0: Back to Business. <i>Clinical Infectious Diseases</i> , 2021, 73, 730-739.	5.8	7
12	Ischemic Benefit and Hemorrhage Risk of Ticagrelor-Aspirin Versus Aspirin in Patients With Acute Ischemic Stroke or Transient Ischemic Attack. <i>Stroke</i> , 2021, 52, 3482-3489.	2.0	9
13	The Emperor's New Clothes: PRospective Observational Evaluation of the Association Between Initial Vancomycin Exposure and Failure Rates Among ADult HospitalizEd Patients With Methicillin-resistant <i>Staphylococcus aureus</i> Bloodstream Infections (PROVIDE). <i>Clinical Infectious Diseases</i> , 2020, 70, 1536-1545.	5.8	106
14	Group-sequential logrank methods for trial designs using bivariate non-competing event-time outcomes. <i>Lifetime Data Analysis</i> , 2020, 26, 266-291.	0.9	4
15	Applying a Risk-benefit Analysis to Outcomes in Tuberculosis Clinical Trials. <i>Clinical Infectious Diseases</i> , 2020, 70, 698-703.	5.8	5
16	Analysis of ordered composite endpoints. <i>Statistics in Medicine</i> , 2020, 39, 602-616.	1.6	13
17	Modern Clinician-initiated Clinical Trials to Determine Optimal Therapy for Multidrug-resistant Gram-negative Infections. <i>Clinical Infectious Diseases</i> , 2020, 71, 433-439.	5.8	1
18	Reply to Villar et al. <i>Clinical Infectious Diseases</i> , 2020, 73, e842-e843.	5.8	2

#	ARTICLE	IF	CITATIONS
19	Ticagrelor and Aspirin or Aspirin Alone in Acute Ischemic Stroke or TIA. <i>New England Journal of Medicine</i> , 2020, 383, 207-217.	27.0	333
20	Ticagrelor Added to Aspirin in Acute Nonsevere Ischemic Stroke or Transient Ischemic Attack of Atherosclerotic Origin. <i>Stroke</i> , 2020, 51, 3504-3513.	2.0	67
21	Presenting Risks and Benefits: Helping the Data Monitoring Committee Do Its Job. <i>Annals of Internal Medicine</i> , 2020, 172, 119.	3.9	18
22	Methodologies for pragmatic and efficient assessment of benefits and harms: Application to the SOCRATES trial. <i>Clinical Trials</i> , 2020, 17, 617-626.	1.6	12
23	Using a Composite Maternalâ€“Infant Outcome Measure in Tuberculosis-Prevention Studies Among Pregnant Women. <i>Clinical Infectious Diseases</i> , 2020, 73, e587-e593.	5.8	2
24	Resist the Temptation of Response-Adaptive Randomization. <i>Clinical Infectious Diseases</i> , 2020, 71, 3002-3004.	5.8	30
25	Human Immunodeficiency Virus Type 1 and Tuberculosis Coinfection in Multinational, Resource-limited Settings: Increased Neurological Dysfunction. <i>Clinical Infectious Diseases</i> , 2019, 68, 1739-1746.	5.8	12
26	Reply to Humphrey and Spafford. <i>Clinical Infectious Diseases</i> , 2019, 69, 1831-1832.	5.8	0
27	Estimated treatment effect of ticagrelor versus aspirin by investigator-assessed events compared with judgement by an independent event adjudication committee in the SOCRATES trial. <i>International Journal of Stroke</i> , 2019, 14, 908-914.	5.9	6
28	The Acute S<u>t</u>roke or Transient Isc<u>h</u>emic Attack Treated with Tic<u>a</u>gre<u>k</u>or and Aspirin for Pr<u>e</u>vention of <u>S</u>troke and Death (THALES) trial: Rationale and design. <i>International Journal of Stroke</i> , 2019, 14, 745-751.	5.9	28
29	Good Studies Evaluate the Disease While Great Studies Evaluate the Patient: Development and Application of a Desirability of Outcome Ranking Endpoint for Staphylococcus aureus Bloodstream Infection. <i>Clinical Infectious Diseases</i> , 2019, 68, 1691-1698.	5.8	42
30	Rapid Molecular Diagnostics to Inform Empiric Use of Ceftazidime/Avibactam and Ceftolozane/Tazobactam Against Pseudomonas aeruginosa: PRIMERS IV. <i>Clinical Infectious Diseases</i> , 2019, 68, 1823-1830.	5.8	37
31	Colistin Versus Ceftazidime-Avibactam in the Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae. <i>Clinical Infectious Diseases</i> , 2018, 66, 163-171.	5.8	485
32	Food and Drug Administrationâ€“mandated Trials of Long-Acting Î²-Agonist Safety in Asthma. Bang for the Buck?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 197, 987-990.	5.6	6
33	1180. Addition of Chronic Kidney Disease Status to Pitt Bacteremia Score Improves Prediction of Mortality in Patients With Carbapenem-Resistant Enterobacteriaceae Infections. <i>Open Forum Infectious Diseases</i> , 2018, 5, S356-S357.	0.9	0
34	1052. Do Healthcare Providers De-Escalate Î²-Lactam (BL) Antibiotic Therapy Based on Results of Antibiotic Susceptibility Testing (AST)? Analysis of Bloodstream Infections (BSI) Caused by Escherichia coli and Klebsiella pneumoniae From the Veterans Health Administration (VHA). <i>Open Forum Infectious Diseases</i> , 2018, 5, S314-S315.	0.9	0
35	1041. How Do Healthcare Providers Approach Empiric Î²-Lactam (BL) Treatment of Bloodstream Infections (BSI) Caused by Gram-Negative Rods (GNRs)? Analysis of Escherichia coli and Klebsiella pneumoniae BSI From the Veterans Health Administration (VHA). <i>Open Forum Infectious Diseases</i> , 2018, 5, S311-S311.	0.9	0
36	1757. Using the Desirability of Outcome Ranking for Management of Antimicrobial Therapy (DOOR-MAT) to Assess Antibiotic Therapy Guided by Rapid Molecular Diagnostics (RMD) in Bloodstream Infection (BSI) Caused by Escherichia coli and Klebsiella pneumoniae. <i>Open Forum Infectious Diseases</i> , 2018, 5, S60-S60.	0.9	2

#	ARTICLE	IF	CITATIONS
37	Trial designs for chemotherapy-induced peripheral neuropathy prevention. <i>Neurology</i> , 2018, 91, 403-413.	1.1	63
38	Similar changes in neuropsychological functioning in english and spanish speaking <scp>HIV</scp> patients. <i>Brain and Behavior</i> , 2018, 8, e01083.	2.2	1
39	Colistin Resistance in Carbapenem-Resistant <i>Klebsiella pneumoniae</i>. Laboratory Detection and Impact on Mortality. <i>Clinical Infectious Diseases</i> , 2017, 64, ciw805.	5.8	150
40	Group-sequential three-arm noninferiority clinical trial designs. <i>Journal of Biopharmaceutical Statistics</i> , 2017, 27, 1-24.	0.8	7
41	Sizing clinical trials when comparing bivariate time-to-event outcomes. <i>Statistics in Medicine</i> , 2017, 36, 1363-1382.	1.6	12
42	Efficacy and safety of ticagrelor versus aspirin in acute stroke or transient ischaemic attack of atherosclerotic origin: a subgroup analysis of SOCRATES, a randomised, double-blind, controlled trial. <i>Lancet Neurology</i> , The, 2017, 16, 301-310.	10.2	174
43	Ticagrelor Versus Aspirin in Acute Embolic Stroke of Undetermined Source. <i>Stroke</i> , 2017, 48, 2480-2487.	2.0	19
44	Risk for Major Bleeding in Patients Receiving Ticagrelor Compared With Aspirin After Transient Ischemic Attack or Acute Ischemic Stroke in the SOCRATES Study (Acute Stroke or Transient Ischemic) <i>Tj ETQq0 0 0.6gBT /Ovz8</i>	0.6	0
45	Fundamentals and Catalytic Innovation: The Statistical and Data Management Center of the Antibacterial Resistance Leadership Group. <i>Clinical Infectious Diseases</i> , 2017, 64, S18-S23.	5.8	8
46	A Prospective Observational Study of the Epidemiology, Management, and Outcomes of Skin and Soft Tissue Infections Due to Carbapenem-Resistant Enterobacteriaceae. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofx157.	0.9	22
47	Carbapenem-Resistant Enterobacteriaceae Infections in Patients on Renal Replacement Therapy. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofx216.	0.9	4
48	Epidemiology and Management of Skin and Soft Tissue Infection (SSTI) Due to Carbapenem-Resistant Enterobacteriaceae: A Report From The Consortium on Resistance against Carbapenems in <i>Klebsiella pneumoniae</i> (CRaCKle). <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.9	0
49	Traumatic Cardiac Injury: Ventricular Perforation Caught on CT. <i>Case Reports in Radiology</i> , 2016, 2016, 1-3.	0.3	3
50	BAC DOOR: A Clinician Ranking Exercise for Better Staphylococcus aureus Bacteremia Trial Design. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.9	0
51	Hospital Readmissions in Patients With Carbapenem-Resistant <i>Klebsiella pneumoniae</i>. <i>Infection Control and Hospital Epidemiology</i> , 2016, 37, 281-288.	1.8	24
52	Using Outcomes to Analyze Patients Rather than Patients to Analyze Outcomes: A Step Toward Pragmatism in Benefit:Risk Evaluation. <i>Statistics in Biopharmaceutical Research</i> , 2016, 8, 386-393.	0.8	93
53	Considerations on Endpoint Selection, Weighting Determination, and Uncertainty Evaluation in the Benefit-Risk Assessment of Medical Product. <i>Statistics in Biopharmaceutical Research</i> , 2016, 8, 417-425.	0.8	4
54	Totality of outcomes: A different paradigm in assessing interventions for treatment of tuberculosis. <i>Journal of Clinical Tuberculosis and Other Mycobacterial Diseases</i> , 2016, 4, 9-13.	1.3	8

#	ARTICLE	IF	CITATIONS
55	Ticagrelor versus Aspirin in Acute Stroke or Transient Ischemic Attack. <i>New England Journal of Medicine</i> , 2016, 375, 35-43.	27.0	424
56	Psychiatric disorders and adherence to antiretroviral therapy among a population of HIV-infected adults in Nigeria. <i>International Journal of STD and AIDS</i> , 2016, 27, 938-949.	1.1	17
57	Impact of therapy and strain type on outcomes in urinary tract infections caused by carbapenem-resistant <i>Klebsiella pneumoniae</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 1203-1211.	3.0	47
58	Residence in Skilled Nursing Facilities Is Associated with Tigecycline Nonsusceptibility in Carbapenem-Resistant <i>Klebsiella pneumoniae</i> . <i>Infection Control and Hospital Epidemiology</i> , 2015, 36, 942-948.	1.8	20
59	Sample Size Considerations in Clinical Trials When Comparing Two Interventions Using Multiple Co-Primary Binary Relative Risk Contrasts. <i>Statistics in Biopharmaceutical Research</i> , 2015, 7, 81-94.	0.8	10
60	Desirability of Outcome Ranking (DOOR) and Response Adjusted for Duration of Antibiotic Risk (RADAR). <i>Clinical Infectious Diseases</i> , 2015, 61, 800-806.	5.8	206
61	Group-Sequential Strategies in Clinical Trials with Multiple Co-Primary Outcomes. <i>Statistics in Biopharmaceutical Research</i> , 2015, 7, 36-54.	0.8	27
62	High Accuracy of Common HIV-Related Oral Disease Diagnoses by Non-Oral Health Specialists in the AIDS Clinical Trial Group. <i>PLoS ONE</i> , 2015, 10, e0131001.	2.5	21
63	Surveillance of Carbapenem-Resistant <i>Klebsiella pneumoniae</i> : Tracking Molecular Epidemiology and Outcomes through a Regional Network. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 4035-4041.	3.2	132
64	Difficulties in Demonstrating Superiority of an Antibiotic for Multidrug-Resistant Bacteria in Nonrandomized Studies. <i>Clinical Infectious Diseases</i> , 2014, 59, 1142-1147.	5.8	9
65	Peripheral neuropathy in HIV: prevalence and risk factors. <i>Aids</i> , 2011, 25, 919-928.	2.2	171
66	Simplification of the Research Diagnosis of HIV-Associated Sensory Neuropathy. <i>HIV Clinical Trials</i> , 2008, 9, 434-439.	2.0	15
67	Data Monitoring in Clinical Trials Using Prediction. <i>Drug Information Journal</i> , 2007, 41, 733-742.	0.5	21
68	Comparison of Direct and Indirect Measurement of LDL-C in HIV-Infected Individuals: ACTG 5087. <i>HIV Clinical Trials</i> , 2007, 8, 45-52.	2.0	23
69	Selegiline Transdermal System (STS) for HIV-Associated Cognitive Impairment: Open-Label Report of ACTG 5090. <i>HIV Clinical Trials</i> , 2007, 8, 437-446.	2.0	30
70	A Randomized Trial Evaluating Prosaptide [®] for HIV-Associated Sensory Neuropathies: Use of an Electronic Diary to Record Neuropathic Pain. <i>PLoS ONE</i> , 2007, 2, e551.	2.5	36
71	When and How Can Endpoints Be Changed after Initiation of a Randomized Clinical Trial. <i>PLOS Clinical Trials</i> , 2007, 2, e18.	3.5	62
72	A comparison of goodness of fit tests for the logistic GEE model. <i>Statistics in Medicine</i> , 2005, 24, 1245-1261.	1.6	43

#	ARTICLE	IF	CITATIONS
73	Goodness of Fit Tests in Mixed Effects Logistic Models Characterized by Clustering. Communications in Statistics - Theory and Methods, 2004, 33, 1139-1155.	1.0	7
74	Goodness of Fit Tests for Logistic GEE Models: Simulation Results. Communications in Statistics Part B: Simulation and Computation, 2004, 33, 247-258.	1.2	11
75	Phase II Evaluation of Low-Dose Oral Etoposide for the Treatment of Relapsed or Progressive AIDS-Related Kaposi's Sarcoma: An AIDS Clinical Trials Group Clinical Study. Journal of Clinical Oncology, 2002, 20, 3236-3241.	1.6	64
76	MEASURING AND TESTING FOR SPATIAL SYNCHRONY. Ecology, 2001, 82, 1668-1679.	3.2	161
77	Measuring and Testing for Spatial Synchrony. Ecology, 2001, 82, 1668.	3.2	9
78	Our Most Important Discovery: The Question. Statistics in Biopharmaceutical Research, 0, , 1-14.	0.8	3
79	Radical Thinking: Scientific Rigor and Pragmatism. Statistics in Biopharmaceutical Research, 0, , 1-13.	0.8	4